Biology Reference
In-Depth Information
Uchida O, Ohmuro S, Hashimoto H, Irikura T (1985) Pharmacokinetics and metabolism
of 3-isobutyryl-2-isopropylpyrazolo [1, 5-a]pyridine (KC-404) in humans. Clin Rep (Kiso to
Rinsho) 19:42-50
Vakkalanka SKVS, Joshi VS, Gopalan B, Gharat LA, Husain R, Khairatkar-Joshi N, Karunakaran
U, Page C (2005) GRC 3886 - A novel selective PDE4 inhibitor with reduced emetic side
effects. World Congress of Inflammation, Sydney 2005 (abstract)
Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sørensen TI, Lange P
(2006) Body mass, fat-free body mass, and prognosis in patients with chronic obstructive
pulmonary disease from a random population sample: findings from the Copenhagen City
Heart Study. Am J Respir Crit Care Med 173:79-83
Vestbo J, Tan L, Atkinson G, Ward J, UK-500, 001 Global Study Team (2009) A controlled trial
of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
Eur Respir J 33:1039-1044
von Richter O, Lahu G, Huennemeyer A, Herzog R, Zech K, Hermann R (2007)
Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Clin Pharmacokinet 46:613-622
Woodrow MD, Ballantine SP, Barker MD, Clarke BJ, Dawson J, Dean TW, Delves CJ, Evans B,
Gough SL, Guntrip SB, Holman S, Holmes DS, Kranz M, Lindvall MK, Lucas FS, Neu M,
Ranshaw LE, Solanke YE, Somers DO, Ward P, Wiseman JO (2009) Quinolines as a novel
structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled adminis-
tration. Bioorg Med Chem Lett 19:5261-5265
Zeller E, Stief HJ, Pflug B, Sastre-y-Hern
´
ndez M (1984) Results of a phase II study of the
antidepressant effect of rolipram. Pharmacopsychiatry 17:188-190
Zhang R, Maratos-Flier E, Flier JS (2009) Reduced adiposity and high-fat diet-induced adipose
inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150:3076-3082
Zussman B, Kelly J, Murdoch RD, Clark DJ, Davie C, Dhaliwal J (1999) The pharmacokinetics
of Ariflo (SB 207499), an orally-active novel and selective PDE4 inhibitor, are similar after
morning and evening dosing. Eur Respir J 14:331s
Zussman B, Kelly J, Murdoch R, Clark D, Cox P, Bush B, Benincosa L (2000) Ariflo, a novel
and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for
drug-drug interactions. Am J Respir Crit Care Med 161:A492
Zussman BD, Benincosa LJ, Webber DM, Clark DJ, Cowley H, Kelly J, Murdoch RD, Upward J,
Wyld P, Port A, Fuder H (2001a) An overview of the pharmacokinetics of cilomilast (Ariflo),
a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers.
J Clin Pharmacol 41:950-958
Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C,
Webber D, Quinlan J, Ritchie SY, Carr A (2001b) Bioavailability of the oral selective
phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy 21:653-660
Zussman BD, Kelly J, Murdoch RD, Clark DJ, Schubert C, Collie H (2001c) Cilomilast: pharma-
cokinetic and pharmacodynamic interactions with digoxin. Clin Ther 23:921-931
Zussman B, Kelly J, Rost K, Clark DJ, Ritchie SY, Bullman SMA (2002) The effect of
renal impairment on the disposition of cilomilast, a novel and selective oral PDE4 inhibitor.
Am J Respir Crit Care Med 165(Suppl):A596
ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K (2001)
Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119:
1661-1670
